ETX-123 / Climb Bio - LARVOL DELTA

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition (BioSpace) - "The Company’s preclinical program targets the Kv7.2/3 potassium channel (Kv7), a target that has clinical validation in pain and epilepsy. The Company has initiated the scaling up synthesis of its lead candidate ETX-123, to enable the initiation of IND-enabling safety studies, with Phase 1 studies planned to initiate in the first half of 2024."

New P1 trial • Preclinical • CNS Disorders • Epilepsy

Eliem Therapeutics Provides Update on Pipeline Progress (Yahoo Finance) - "ETX-155 program: ETX-155 is a novel GABAA receptor positive allosteric modulator (GABAA PAM) that is being developed for the treatment of major depressive disorder (MDD) and epilepsy....Kv7.2/3 channel opener program: The Company’s preclinical program targets the Kv7.2/3 potassium channel (Kv7), a target that has clinical validation in pain and epilepsy....the initiation of IND-enabling safety studies, expected in the first quarter of 2023, with Phase 1 studies planned to initiate in the first half of 2024."

IND • New P1 trial • CNS Disorders • Epilepsy